这 Pharmaceuticals Benefits Advisory Committee (PBAC) has recommended the listing of quadrivalent influenza vaccine (QIV, Vaxigrip TetraTM) on the National Immunisation Program (NIP) for the prevention of seasonal influenza in children aged 6 months to <5 years as well as for individuals who are currently eligible for seasonal influenza vaccination through the NIP in 2020.
关于 MVEC
墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。